^
    5ms
    Comparison Between EGFR PCR Alone and NGS with Gene Fusion PCR for Detecting Oncogenic Driver Alteration in Thai NSCLC Patients (IASLC-WCLC 2024)
    However, NGS had a 12-day longer TAT compared to EGFR PCR. Gene fusion-panel PCR and NGS identified an additional 11.6% of patients harboring actionable alterations who may benefit from FDA-approved targeted therapies.
    Clinical • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • EGFR G719X • KRAS G12 • EGFR positive • EGFR L747P • EGFR L861R
    |
    cobas® EGFR Mutation Test v2 • Idylla™ GeneFusion Assay • Idylla™ BRAF Mutation Test • Idylla™ EGFR Mutation Test
    1year
    EXCLAIM: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=334, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting
    Enrollment closed • HER2 exon 20
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    Exkivity (mobocertinib)
    over1year
    EXCLAIM: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=334, Recruiting, Takeda | Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Mar 2025
    Trial completion date • Trial primary completion date • HER2 exon 20
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    Exkivity (mobocertinib)
    almost2years
    EXCLAIM: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=334, Recruiting, Takeda | Active, not recruiting --> Recruiting
    Enrollment open • HER2 exon 20
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    Exkivity (mobocertinib)
    2years
    Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. (PubMed, Thorac Cancer)
    The success rate of ODxTT is slightly inferior to that of cobas EGFR. ODxTT shared a high concordance rate and k-coefficient with cobas EGFR in detecting EGFR mutations, but discordant results between the two tests were observed in a few cases, mainly due to the difference of detectable EGFR variants.
    Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR L861R • EGFR E746 • EGFR L747_P753delinsS
    |
    cobas® EGFR Mutation Test v2 • Oncomine™ Dx Target Test
    over2years
    Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. (PubMed, Genes (Basel))
    The p.L861Q localized in exon 21 of the EGFR gene was the most common mutation identified in our patients (35.3%), whereas the "classic" EGFR mutations such as Del19 and p.L858R were found in 23.5% and 11.7% of the cases, respectively. Interestingly, most of p.L861X mutation-carrying patients showed good response to TKI treatment. Altogether, our findings suggest a particular distribution of the EGFR-TKIs sensitivity mutations in Tunisian NSCLC patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR exon 18 mutation • EGFR negative • EGFR L861R • EGFR E746
    over2years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Trial primary completion date: Mar 2022 --> Oct 2022
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    over2years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=324, Active, not recruiting, Takeda | Trial primary completion date: Mar 2022 --> Mar 2023
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    Exkivity (mobocertinib)
    over2years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2; Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    Exkivity (mobocertinib)
    3years
    An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report. (PubMed, Medicine (Baltimore))
    The patient was diagnosed with advanced lung cancer that had progressed after previous osimertinib drug therapy, based on the clinical course and imaging findings...The patient was then administered afatinib at 30 mg quaque die combined with bevacizumab at 300 mg every 2 weeks...The family elected to forgo further therapy due to the patient's age and enrolled in hospice care, passing 14 months after the initial diagnosis. EGFR-L861R mutation could help predict the sensitivity of patients with advanced NSCLC to TKIs.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861R
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Gilotrif (afatinib)
    over3years
    A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. (PubMed, Ann Palliat Med)
    After 1 month of treatment, the patient achieved central nervous system (CNS) response, and at the time of this manuscript's submission, he had maintained stable disease (SD) for more than 1 year. To our knowledge, this study provides the first clinical evidence that the administration of osimertinib at 160 mg once daily can achieve an encouraging, durable response in an NSCLC patient with LM carrying EGFR G719S and L861Q.
    Clinical • Clinical protocol • Retrospective data • Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719S • EGFR G719S + EGFR L861Q • EGFR L861R
    |
    Tagrisso (osimertinib)
    over3years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=395, Recruiting, Millennium Pharmaceuticals, Inc. | Trial primary completion date: May 2020 --> Mar 2022
    Clinical • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    almost4years
    Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. (PubMed, Clin Lung Cancer)
    Initiation of targeted therapy for advanced NSCLC was feasible based only on identification of actionable mutations by cfDNA testing in 9% of the cases for which tissue diagnosis could not be obtained. Actionable targets were identified by cfDNA in 20% of the samples sent at diagnosis. A substantial number of patients benefited from cfDNA testing at initial diagnosis because it identified actionable mutations that led to appropriate targeted treatments.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B) • CD74 (CD74 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • RET fusion • MET exon 14 mutation • EML4-ALK fusion • ALK fusion • EGFR L861Q • RET mutation • KIF5B-RET fusion • ROS1 fusion • EGFR L861R • ALK-ROS1 fusion • NTRK fusion
    |
    Guardant360® CDx
    almost4years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    almost4years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=331, Recruiting, Millennium Pharmaceuticals, Inc. | Active, not recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    4years
    [VIRTUAL] NSCLC Patients With Rare EGFR Mutations in Exons 18 and 19 Benefits From Treatment With EGFR Tyrosine Kinase Inhibitors (IASLC-WCLC 2020)
    Our study contributes an incremental step in understanding the clinical responses of patients with rare EGFR mutations located in exon 18 and 19. Understanding the treatment responses and survival outcomes are critical in the optimal treatment management and improving the survival outcomes of patients with rare EGFR mutations.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747P • EGFR exon 18 mutation • EGFR L861R • EGFR E746
    over4years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Chest Hospital
    Clinical • New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    over4years
    Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR. (PubMed, Lung Cancer)
    No abstract available
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861R
    |
    Gilotrif (afatinib)
    over4years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=306, Active, not recruiting, Millennium Pharmaceuticals, Inc. | N=97 --> 306
    Clinical • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    almost5years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=97, Active, not recruiting, Millennium Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    almost5years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=97, Recruiting, Millennium Pharmaceuticals, Inc. | Active, not recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    almost5years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=97, Active, not recruiting, Millennium Pharmaceuticals, Inc. | N=341 --> 97
    Clinical • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    5years
    AP32788-15-101: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=341, Active, not recruiting, Millennium Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)